These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16264955)

  • 1. [Updating in prevention and treatment of prostate cancer].
    Marzo Castillejo M; Peña López F; Alonso Coello P; Mascort Roca JJ
    Aten Primaria; 2002 Jun; 30(1):57-63. PubMed ID: 12106580
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management.
    Pollack A; Pra AD
    Lancet; 2024 Jun; 403(10442):2353-2355. PubMed ID: 38763152
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges in clinical trials for high-risk but curable prostate cancer.
    Dorff TB; Bryce AH
    Cancer; 2024 May; 130(9):1575-1576. PubMed ID: 38340332
    [No Abstract]   [Full Text] [Related]  

  • 4. RADICALS-HD sheds light on the role of ADT addition to post-operative radiotherapy.
    Romero D
    Nat Rev Clin Oncol; 2024 Aug; 21(8):565. PubMed ID: 38816606
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate Cancer.
    Churchill TW; Smith MR; Michaelson MD; Lee RJ; Guseh JS; Wasfy MM; Meneely E; Olivier K; Baggish AL; Saylor PJ
    J Am Soc Echocardiogr; 2024 Jul; 37(7):706-708. PubMed ID: 38499230
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
    Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
    J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer.
    Maccarinelli F; Coltrini D; Mussi S; Bugatti M; Turati M; Chiodelli P; Giacomini A; De Cillis F; Cattane N; Cattaneo A; Ligresti A; Asperti M; Poli M; Vermi W; Presta M; Ronca R
    Cell Death Discov; 2023 Mar; 9(1):81. PubMed ID: 36872341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
    Tang D; He J; Dai Y; Geng X; Leng Q; Jiang H; Sun R; Xu S
    Cancer Gene Ther; 2022 May; 29(5):543-557. PubMed ID: 33854217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.
    Xu H; Sun Y; Huang CP; You B; Ye D; Chang C
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.
    Luo J; Lee SO; Cui Y; Yang R; Li L; Chang C
    Oncotarget; 2015 Sep; 6(29):27555-65. PubMed ID: 26342197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.
    Chen K; Wu K; Jiao X; Wang L; Ju X; Wang M; Di Sante G; Xu S; Wang Q; Li K; Sun X; Xu C; Li Z; Casimiro MC; Ertel A; Addya S; McCue PA; Lisanti MP; Wang C; Davis RJ; Mardon G; Pestell RG
    Cancer Res; 2015 May; 75(10):1992-2004. PubMed ID: 25769723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
    Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor is a tumor suppressor and proliferator in prostate cancer.
    Niu Y; Altuwaijri S; Lai KP; Wu CT; Ricke WA; Messing EM; Yao J; Yeh S; Chang C
    Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12182-7. PubMed ID: 18723679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto H; Messing EM; Chang C
    Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
    [No Abstract]   [Full Text] [Related]  

  • 15. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: non-metastatic.
    Wilt T
    Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer (non-metastatic).
    Wilt T
    Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.